Arcam AB plans to look into strategic alternatives regarding DiSanto Technology, an Arcam company which offers contract manufacturing of orthopedic implants.

As part of this process, the company is considering restructuring, full or partial separation of DTI via a spin-off, sale, joint venture, strategic collaboration or another transaction. 

Arcam’s objective is to strengthen DTI’s ability to serve as a contract manufacturing partner to orthopedic customers seeking to combine the benefits of additive manufacturing (AM) with traditional manufacturing capabilities.

‘There can be no assurance that this review will result in a transaction,’ the company said in a press release. ‘Although Arcam expects to proceed in a timely manner, there is no timetable for completion of the review process and the company does not intend to announce any updates other than what is required by law and the stock exchange rules.’

This story is reprinted from material from Arcamwith editorial changes made by Materials Today. The views expressed in this article do not necessarily represent those of Elsevier.